{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:21:18Z","timestamp":1792120878199,"version":"4.4.0"},"reference-count":19,"publisher":"Pan African Medical Journal","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pan Afr Med J"],"abstract":"<jats:p>Severe asthma is a chronic condition that often requires oral corticosteroid (OCS) therapy, which, when prolonged, may lead to significant adverse effects, including secondary adrenal insufficiency. Advances in biologic therapies have allowed many patients to reduce or discontinue OCS. We describe the clinical course and outcomes of six patients with severe corticosteroid-dependent asthma who underwent a structured OCS tapering protocol under endocrinological supervision. All patients had a history of prolonged OCS use (mean duration &gt;10 years), high-dose inhaled corticosteroids (ICS), and biologic therapy. Adrenal insufficiency was confirmed in three patients (50%), who required continued hydrocortisone replacement due to persistent hypothalamic-pituitary-adrenal (HPA) axis suppression. The other three patients successfully discontinued corticosteroids and demonstrated HPA axis recovery. Notably, no asthma exacerbations occurred during the tapering process. A structured, multidisciplinary corticosteroid tapering protocol is both feasible and safe in patients with severe asthma, particularly when guided by endocrine assessment. ICS exposure may contribute to adrenal suppression, highlighting the need for comprehensive hormonal evaluation in this population.<\/jats:p>","DOI":"10.11604\/pamj.2025.52.44.48421","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T15:10:44Z","timestamp":1762960244000},"source":"Crossref","is-referenced-by-count":1,"title":["Structured tapering of oral corticosteroids in patients with severe asthma at risk of secondary adrenal insufficiency: a case series"],"prefix":"10.11604","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-8772-4565","authenticated-orcid":false,"given":"Manuel","family":"Carpio Salmer\u00f3n","sequence":"first","affiliation":[{"name":"Servicio de Endocrinolog\u00eda y Nutrici\u00f3n, Hospital General Universitario Santa Luc\u00eda, Cartagena, Espa\u00f1a"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian Heredia","family":"Carrillo","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/051fvq837","id-type":"ROR","asserted-by":"publisher"}],"name":"Santa Luc\u00eda University General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8954-8942","authenticated-orcid":false,"given":"Luis Marin","family":"Martinez","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/051fvq837","id-type":"ROR","asserted-by":"publisher"}],"name":"Santa Luc\u00eda University General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2459-8655","authenticated-orcid":false,"given":"Georgios","family":"Kyriakos","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/051fvq837","id-type":"ROR","asserted-by":"publisher"}],"name":"Santa Luc\u00eda University General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4870","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med. 2012;18(5):716-25. PubMed | Google Scholar","DOI":"10.1038\/nm.2678"},{"key":"ref1","unstructured":"Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. 2024 Update."},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Waljee AK, Rogers MA, Lin P, Singal AG, Stein JD, Marks RM et al. Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. BMJ. 2017;357:j1415. PubMed | Google Scholar","DOI":"10.1136\/bmj.j1415"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Barnes PJ. Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2013;131(3):636-45. Google Scholar","DOI":"10.1016\/j.jaci.2012.12.1564"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189-97. PubMed | Google Scholar","DOI":"10.1056\/NEJMoa1403291"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M et al. Benralizumab, an anti-interleukin-5 receptor monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA). Lancet. 2016;388(10056):2128-41. PubMed | Google Scholar","DOI":"10.1016\/S0140-6736(16)31322-8"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Rabe KF, Nair P, Brusselle G, Maspero J, Castro M, Sher L et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475-85. PubMed | Google Scholar","DOI":"10.1056\/NEJMoa1804093"},{"key":"ref7","unstructured":"Heaney LG, Busby J, Bradding P, Chaudhuri R, Mansur AH, Niven RM et al. Biomarkers of treatment response in severe asthma: a systematic review. Clin Exp Allergy. 2019;49(4):409-1."},{"key":"ref8","unstructured":"Zaman N, Hassan M, Ahmed S. Secondary Adrenal Insufficiency: A Review of Clinical Features, Diagnosis and Management. BIRDEM Med J. 2015;5(2):92-8."},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Zuechner M, Leelarathna L. Steroid-induced adrenal insufficiency: a hidden danger. BMJ. 2021;375:e065137.","DOI":"10.1136\/bmj-2021-065137"},{"key":"ref10","unstructured":"Menzies-Gow A. Modificado de: Menzies-Gow et al., 2022. En: GEMA 5.2. Gu\u00eda Espa\u00f1ola para el Manejo del Asma. Madrid: Sociedad Espa\u00f1ola de Neumolog\u00eda y Cirug\u00eda Tor\u00e1cica (SEPAR); 2022."},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Todd GRG, Acerini CL, Ross-Russell R, Zahra S, Warner JT, McCance D. Suppression of the hypothalamic-pituitary-adrenal axis in asthmatic children treated with high-dose fluticasone propionate. Lancet. 1996;348(9023):27-9.","DOI":"10.1016\/S0140-6736(96)03339-9"},{"key":"ref12","unstructured":"Gulliver T, Eid N, Spier S. Adrenal suppression from inhaled corticosteroids: clinical presentation and diagnostic evaluation. Ann Allergy Asthma Immunol. 2020;125(5):502-10."},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198-207. PubMed | Google Scholar","DOI":"10.1056\/NEJMoa1403290"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Charmandari E, Nicolaides NC, Chrousos GP. Adrenal insufficiency. Lancet. 2014;383(9935):2152-67. PubMed | Google Scholar","DOI":"10.1016\/S0140-6736(13)61684-0"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Joseph RM, Hunter AL, Ray DW, Dixon WG. Systemic glucocorticoid therapy and adrenal insufficiency in adults: a systematic review. Semin Arthritis Rheum. 2016;46(1):133-41. PubMed | Google Scholar","DOI":"10.1016\/j.semarthrit.2016.03.001"},{"key":"ref16","unstructured":"Vogelmeier CF, Asciuto G, Bjermer L, Bourdin A, Dorow P, Fielding S et al. Clinical implications of corticosteroid-related adverse events in asthma and COPD. Respir Med. 2020;170:106021."},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Menzies-Gow A, Gurnell M, Heaney LG, Corren J, Bel EH, Maspero J et al. Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study. Lancet Respir Med. 2022;10(1):47-58. PubMed | Google Scholar","DOI":"10.1016\/S2213-2600(21)00352-0"},{"key":"ref18","unstructured":"P\u00e9rez Conesa M. Gu\u00eda pr\u00e1ctica para el uso de corticoides y terapias inmunosupresoras. Madrid: Sociedad Espa\u00f1ola de Medicina Interna (SEMI); 2013."}],"container-title":["Pan African Medical Journal"],"original-title":[],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T15:10:47Z","timestamp":1762960247000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.panafrican-med-journal.com\/content\/article\/52\/44\/full\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":19,"URL":"https:\/\/doi.org\/10.11604\/pamj.2025.52.44.48421","relation":{},"ISSN":["1937-8688"],"issn-type":[{"value":"1937-8688","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"article-number":"48421"}}